EHRA 2025 - SINGLE SHOT CHAMPION finds PFA with the FARAPULSE PFA System noninferior to cryoballoon ablation with the Arctic Front Cryoballoon.
Prof Tobias Reichlin (University of Bern, Bern, CH) joins us on-site at EHRA Congress 2025 to discuss the investigator-initiated, multicenter, randomized SINGLE SHOT CHAMPION trial (NCT05534581; Insel Gruppe AG, University Hospital Bern) with blinded endpoint adjudication. SINGLE SHOT CHAMPION investigated the safety and efficacy of PFA with the FARAPULSE PFA System (Boston Scientific) or cryoballoon ablation with the Arctic Front Cryoballoon (Medtronic) in patients with symptomatic PAF undergoing their first PVI procedure. The primary endpoint was time to first recurrence of any atrial tachyarrhythmia.
Findings showed that freedom from recurrence of atrial fibrillation occurred in 62.9% of patients in the pulsed-field ablation group, and in 49% of those in the cryoballoon group, meeting the criteria for noninferiority.
Interview Questions:
1. What is the importance of this study?
2. What was the study design and patient population?
3. What were the key findings?
5. Based on these findings, how do you anticipate the adoption of pulsed field ablation will evolve in clinical practice?
+. How might these results influence guidelines?
7. What are the next research questions that should be addressed regarding PFA?
Recorded on-site at EHRA in Vienna, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographers: Oliver Miles, David Ben-Harosh
Support: This is an independent interview produced by Arrhythmia Academy.
Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Prof Tobias Reichlin (University of Bern, Bern, CH) joins us on-site at EHRA Congress 2025 to discuss the investigator-initiated, multicenter, randomized SINGLE SHOT CHAMPION trial (NCT05534581; Insel Gruppe AG, University Hospital Bern) with blinded endpoint adjudication. SINGLE SHOT CHAMPION investigated the safety and efficacy of PFA with the FARAPULSE PFA System (Boston Scientific) or cryoballoon ablation with the Arctic Front Cryoballoon (Medtronic) in patients with symptomatic PAF undergoing their first PVI procedure. The primary endpoint was time to first recurrence of any atrial tachyarrhythmia.
Findings showed that freedom from recurrence of atrial fibrillation occurred in 62.9% of patients in the pulsed-field ablation group, and in 49% of those in the cryoballoon group, meeting the criteria for noninferiority.
Interview Questions:
1. What is the importance of this study?
2. What was the study design and patient population?
3. What were the key findings?
5. Based on these findings, how do you anticipate the adoption of pulsed field ablation will evolve in clinical practice?
+. How might these results influence guidelines?
7. What are the next research questions that should be addressed regarding PFA?
Recorded on-site at EHRA in Vienna, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographers: Oliver Miles, David Ben-Harosh
Support: This is an independent interview produced by Arrhythmia Academy.
Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
- Category
- Cardiology

Be the first to comment